MEK Inhibitor News and Research

RSS

Promising results for dabrafenib in advanced melanoma

The BRAF inhibitor dabrafenib shows promising results for treatment of advanced melanoma, both alone and in combination with the MEK inhibitor trametinib, show results from two studies presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.

8 Jun 2012

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Promising data on MEK162 in an ongoing Phase 2 trial of patients with BRAF and NRAS mutated advanced melanoma was presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

5 Jun 2012

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

Nature journal publishes first volume of Cancer Cell Line Encyclopedia

The goal of cancer treatment is to match the right drug to the right target in the right patient. But before such "personalized" drugs can be developed, more knowledge is needed about specific genomic alterations in cancers and their sensitivity to potential therapeutic agents.

29 Mar 2012

Melanoma drug makes pre-existing cells with RAS mutation grow into skin squamous cell cancers

Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer.

18 Jan 2012

Combination of MEK inhibitors and nilotinib can overcome CML resistance to targeted drug

Cancer Research UK-funded scientists at The Institute of Cancer Research (ICR) have revealed a technique to kill chronic myeloid leukaemia (CML) cells that have stopped responding to a targeted drug, according to research published in Cancer Cell today.

9 Dec 2011

Receptor tyrosine kinases control PI3K signaling in human KRAS mutant colorectal cancers

Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts General Hospital Cancer Center, Boston, has now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers - combine them with inhibitors of the MEK/ERK signaling pathway.

11 Oct 2011

Array announces results from selumetinib Phase 2 combination study on KRAS-mutant NSCLC

Array BioPharma Inc. today announced results from a randomized Phase 2 placebo-controlled study conducted by AstraZeneca comparing the efficacy of selumetinib in combination with docetaxel with docetaxel alone in the second-line treatment of 87 patients prospectively selected with KRAS-mutant, locally advanced or metastatic non-small cell lung cancer.

30 Sep 2011

Plexxikon, Genentech enter PLX4032 co-promotion agreement

Plexxikon, Inc., announced today that it has signed an agreement with Genentech to co-promote PLX4032 (RG7204) in the United States. PLX4032, an oral, novel kinase inhibitor that targets the oncogenic BRAF mutation, is being tested in late-stage clinical trials for the treatment of metastatic melanoma.

7 Jan 2011

Merck, sanofi-aventis enter global cancer research and development agreement

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Merck, has signed a worldwide research and development agreement with sanofi-aventis U.S. Inc., under which Merck Serono and sanofi-aventis U.S. Inc. will collaboratively investigate novel experimental combinations of agents that could block specific pathways in cancer cells. This collaboration could deliver novel targeted oncology treatments with high therapeutic potential.

17 Dec 2010

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

This past summer saw a revolution in melanoma therapy. Patients whose melanoma lesions contain a mutation in the BRAF gene were successfully treated with a BRAF-specific inhibitor, PLX4032. Reports of the drug trial described shrinking tumors and improved health. Yet seven months after therapy began the tumors returned and resumed growing. Now, scientists at The Wistar Institute explain why: the tumor learns to signal around the blocked gene by adjusting its molecular wiring.

15 Dec 2010

Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

ZIOPHARM Oncology, Inc. announced today that new preclinical data on the novel mechanism of its organic arsenic darinaparsin (ZIO-101) in various lymphoma models were presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology in Orlando Florida.

6 Dec 2010

Plexxikon's PLX4032 shows positive data in patients with metastatic melanoma

Plexxikon today announced positive preliminary data from a pivotal Phase 2 clinical trial of PLX4032 (RG7204) in metastatic melanoma, showing significant tumor shrinkage in the majority of patients.

8 Nov 2010

Melanoma Research Alliance announces grant to support six research programs

The Melanoma Research Alliance today announced $5.2 million in grants to support six multidisciplinary teams pursuing innovative, translational research approaches designed to benefit melanoma patients.

21 Aug 2010

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma Inc. today reported financial results for the fourth quarter and full year of fiscal 2010.

10 Aug 2010

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Ardea Biosciences, Inc., a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and financial results for the second quarter and six months ended June 30, 2010.

7 Aug 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Ardea Biosciences, Inc. a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

7 May 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2010.

4 May 2010

Investment report on Array BioPharma

MicroStockProfit.com announces an investment report featuring Array BioPharma Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

21 Apr 2010

Array BioPharma signs agreement with Novartis for worldwide development of ARRY-162

Array BioPharma Inc. today announced that it has entered into an agreement with Novartis for the worldwide development of the small-molecule MEK inhibitors ARRY-162, currently in a Phase 1 cancer trial, its back-up, ARRY-300, and other MEK inhibitors.

20 Apr 2010